Aurinia to Attend July 2024 Investor Healthcare Conferences

ROCKVILLE, Md. & EDMONTON, Alberta-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) has announced that its management team will engage in one-on-one meetings with investors at two upcoming events. The first event is the Leerink Partners Therapeutics Forum: I&I and Metabolism, taking place on July 9-10, 2024, in Boston. Following this, the team will participate in the 3rd Annual H.C. Wainwright Virtual Kidney Conference on July 15, 2024.

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company dedicated to creating therapies for individuals living with autoimmune diseases, particularly those with high unmet medical needs. A significant milestone for the company was achieved in January 2021 with the introduction of LUPKYNIS® (voclosporin). This product holds the distinction of being the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis.

The company's main office is located in Edmonton, Alberta, while its U.S. commercial office operates out of Rockville, Maryland. Aurinia Pharmaceuticals has a global focus in its development efforts, aiming to address the needs of patients worldwide.